Evidence map›Paper›PMID 27149518›Full record

ArticlePloS one2016

Determination of the CD148-Interacting Region in Thrombospondin-1.

Keiko Takahashi, Katherine Sumarriva, Rachel Kim, Rosie Jiang, Dana M Brantley-Sieders, Jin Chen, Raymond L Mernaugh, Takamune Takahashi

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
0.5field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 19 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Agonistic anti-CD148 monoclonal antibody attenuates diabetic nephropathy in mice.American journal of physiology. Renal physiology · 2020
    Article
  12. Article
  13. Integration of pro- and anti-angiogenic signals by endothelial cells.Journal of cell communication and signaling · 2018
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Keiko TakahashiDepartment of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee, United States of America.
Katherine SumarrivaDepartment of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee, United States of America.
Rachel KimDepartment of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee, United States of America.
Rosie JiangDepartment of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee, United States of America.
Dana M Brantley-SiedersDepartment of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee, United States of America.
Jin ChenDepartment of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee, United States of America.
Raymond L MernaughDepartment of Biochemistry, Vanderbilt University School of Medicine, Nashville, Tennessee, United States of America.
Takamune TakahashiDepartment of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee, United States of America.
Vanderbilt University · US

Funding

Role of CD148 Tyrosine Phosphatase in Diabetic NephropathyR01DK097332 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI TAKAHASHI, TAKAMUNE · 2012 to 2016
$1.7M
Role of CD148 Tyrosine Phosphatase in AngiogenesisR21HL109715 · NHLBI · VANDERBILT UNIVERSITY · PI TAKAHASHI, TAKAMUNE · 2013 to 2014
$424k
NHLBI NIH HHS R21 HL109715NIDDK NIH HHS R01 DK097332
6 · The paper itself

Abstract

CD148 is a transmembrane protein tyrosine phosphatase that is expressed in multiple cell types, including vascular endothelial cells and duct epithelial cells. Previous studies have shown a prominent role of CD148 to reduce growth factor signals and suppress cell proliferation and transformation. Further, we have recently shown that thrombospondin-1 (TSP1) serves as a functionally important ligand for CD148. TSP1 has multiple structural elements and interacts with various cell surface receptors that exhibit differing effects. In order to create the CD148-specific TSP1 fragment, here we investigated the CD148-interacting region in TSP1 using a series of TSP1 fragments and biochemical and biological assays. Our results demonstrate that: 1) CD148 binds to the 1st type 1 repeat in TSP1; 2) Trimeric TSP1 fragments that contain the 1st type repeat inhibit cell proliferation in A431D cells that stably express wild-type CD148 (A431D/CD148wt cells), while they show no effects in A431D cells that lack CD148 or express a catalytically inactive form of CD148. The anti-proliferative effect of the TSP1 fragment in A431D/CD148wt cells was largely abolished by CD148 knockdown and antagonized by the 1st, but not the 2nd and 3rd, type 1 repeat fragment. Furthermore, the trimeric TSP1 fragments containing the 1st type repeat increased the catalytic activity of CD148 and reduced phospho-tyrosine contents of EGFR and ERK1/2, defined CD148 substrates. These effects were not observed in the TSP1 fragments that lack the 1st type 1 repeat. Last, we demonstrate that the trimeric TSP1 fragment containing the 1st type 1 repeat inhibits endothelial cell proliferation in culture and angiogenesis in vivo. These effects were largely abolished by CD148 knockdown or deficiency. Collectively, these findings indicate that the 1st type 1 repeat interacts with CD148, reducing growth factor signals and inhibiting epithelial or endothelial cell proliferation and angiogenesis.

Indexed as

AnimalsBinding SitesCell ProliferationCells, CulturedEndothelial CellsGene Knockdown TechniquesHumansImmunoblottingImmunoprecipitationMice, Inbred C57BLNeovascularization, PhysiologicPeptide FragmentsProtein Tyrosine PhosphatasesReceptor-Like Protein Tyrosine Phosphatases, Class 3Thrombospondin 1Peptide FragmentsProtein Tyrosine PhosphatasesPtprj protein, mouseReceptor-Like Protein Tyrosine Phosphatases, Class 3Thbs1 protein, mouseThrombospondin 1

Identifiers

PMID27149518
PMCPMC4858292
OpenAlexW2346709990

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.